$Profile of brentuximab vedotin and its potential in the treatment of relapsed or refractory Hodgkin lymphoma$
Código QR

Código QR

Profile of brentuximab vedotin and its potential in the treatment of relapsed or refractory Hodgkin lymphoma

Sam Mayes,1 Adam Gibb,1 Tim Illidge1,21The Christie Hospital NHS Foundation, Wilmslow Road, 2School of Cancer and Enabling Sciences, University of Manchester, Manchester Academic Health Sciences Centre, UKAbstract: Treatment of primary refractory and relapsed classical Hodgkin lymphoma remains chall...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Illidge T, Gibb A, Mayes S
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2012
Materias:	Diseases of the blood and blood-forming organs RC633-647.5
Acceso en línea:	https://doaj.org/article/779540bde3854435a910b61767fd764a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

The Evolving Role of Brentuximab Vedotin in Classical Hodgkin Lymphoma
por: Lai C, et al.
Publicado: (2019)

TREATMENT OF RELAPSED, REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
por: Ebru Pekgüç, et al.
Publicado: (2021)

Clinical potential of carfilzomib in the treatment of relapsed and refractory multiple myeloma
por: Gupta VA, et al.
Publicado: (2013)

MEDICAL TREATMENT IN HODGKIN LYMPHOMA
por: Nilgun Kurucu
Publicado: (2021)

ANTICARDIOLIPINIC ANTIBODIES IN NON-HODGKIN LYMPHOMA
por: Sanda Buruiana, et al.
Publicado: (2021)

Intrasinusoidal Hodgkin Lymphoma; A Mimic of Anaplastic Large Cell Lymphoma
por: John R. Krause, et al.
Publicado: (2021)

The Use of Etoposide, Ara-Cytarabine, and Melphalan (EAM) Conditioning Chemotherapy in Autologous Stem Cell Transplantation (ASCT) for a Patient with Relapsed Hodgkin’s Lymphoma
por: Eko A. Pangarsa, et al.
Publicado: (2021)

The European Medicines Agency Review of Tafasitamab in Combination With Lenalidomide for the Treatment of Adult Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
por: Julio Delgado, et al.
Publicado: (2021)

MicroRNA dysregulation in B-cell non-Hodgkin lymphoma
por: Lim EL, et al.
Publicado: (2013)

Yttrium-90 ibritumomab tiuxetan in the treatment of non-Hodgkin lymphoma
por: McKinney MS, et al.
Publicado: (2014)

Reduced intensity treatment in early-stage Hodgkin&rsquo;s lymphoma
por: Armitage JO, et al.
Publicado: (2011)

PROGNOSIS FACTORS IN AGGRESSIVE NON-HODGKIN LYMPHOMAS WITH PRIMARY INVOLVEMENT OF THE SPLEEN
por: Larisa Musteata, et al.
Publicado: (2021)

mTOR inhibitor in the treatment of Hodgkin&rsquo;s lymphoma: a case report
por: Provencio M., et al.
Publicado: (2011)

CLINICAL CHARACTERISTICS, AND SURVIVAL RATE OF ELDERLY PATIENTS WITH NON-HODGKIN'S LYMPHOMAS WITH PRIMARY INVOLVEMENT OF PERIPHERAL LYMPH NODES
por: Tomacinschii Victor, et al.
Publicado: (2021)

Gemtuzumab ozogamicin is efficacious in attaining complete remission in relapsed/refractory acute leukemia prior to hematopoietic cell transplant: A case series
por: Giancarlo Fatobene, et al.
Publicado: (2021)

Outcomes and relapse patterns following chemotherapy in advanced Hodgkin lymphoma in the positron emission tomography era
por: Lapuz C, et al.
Publicado: (2018)

Bone marrow necrosis in a patient with advanced Hodgkin's lymphoma after G-CSF and Plerixafor treatment during harvesting for autologous bone marrow transplantation: is it possible?
por: Najmaddin Khoshnaw, et al.
Publicado: (2021)

The absolute lymphocyte/monocyte ratio recovery during ABVD treatment cycles is not significantly impacted by the use of myeloid growth factors and predicts clinical outcomes in classical Hodgkin lymphoma regardless of their use
por: Kaufman GP, et al.
Publicado: (2014)

Developments in anaplastic large-cell lymphoma: targeting the anaplastic lymphoma kinase
por: Farina F, et al.
Publicado: (2014)

Advances in the diagnosis and management of lymphoma
por: Matasar MJ, et al.
Publicado: (2012)

THE SMALLEST PRIMARY BONE LYMPHOMA
por: Fatma Burçin KURTİPEK, et al.
Publicado: (2021)

MYC as therapeutic target in leukemia and lymphoma
por: Cortiguera MG, et al.
Publicado: (2015)

IMMUNE THROMBOCYTOPENIA RELAPSE POST COVID-19 VACCINE IN YOUNG MALE PATIENT
por: Hana Qasim
Publicado: (2021)

Profile of elotuzumab and its potential in the treatment of multiple myeloma
por: Liu YC, et al.
Publicado: (2014)

Peripheral T cell lymphoma: clinical utility of romidepsin
por: Sawey K, et al.
Publicado: (2012)

Preserving fertility in young patients with lymphoma: an overview
por: Patel B, et al.
Publicado: (2014)

MicroRNAs as B-cell lymphoma biomarkers
por: Manterola L, et al.
Publicado: (2015)

Mogamulizumab for the treatment of adult T-cell leukemia/lymphoma
por: Yoshimitsu M, et al.
Publicado: (2014)

THREE CASES WITH BURKITT LYMPHOMA PRESENTING WITH CHOLESTASIS
por: Fatma Tuba YILDIRIM, et al.
Publicado: (2021)

CASE REPORT: FOLLICULAR LYMPHOMA PRESENTED WITH CHYLOTHORAX
por: Senem MARAL, et al.
Publicado: (2021)

A CASE OF REFRACTORY IMMUNE THROMBOCYTOPENIA APPLIED WITH AUTOLOGOUS HEMATOPOETIC STEM CELL TRANSPLANTATION
por: Mine KARADENIZ, et al.
Publicado: (2021)

Emerging role of SOX11 in mantle cell lymphoma
por: Kuci V, et al.
Publicado: (2015)

A CASE OF MULTI REGIONAL PRIMARY MUSCLE LYMPHOMA
por: Beyza OLUK, et al.
Publicado: (2021)

A RARE CASE: POSTTRANSPLANT NK/T CELL LYMPHOMA
por: Pınar Tığlıoğlu, et al.
Publicado: (2021)

Profile of inotuzumab ozogamicin and its potential in the treatment of acute lymphoblastic leukemia
por: Thomas X
Publicado: (2014)

Immune targeted therapy for diffuse large B cell lymphoma
por: Yaxin Zheng, et al.
Publicado: (2021)

Emerging targets in human lymphoma: targeting the MYD88 mutation
por: Wang JQ, et al.
Publicado: (2013)

BURKITT LYMPHOMA PRESENTING WITH EYE AND KIDNEY INVOLVEMENT: CASE REPORT
por: Aslı Turgutoğlu Yılmaz, et al.
Publicado: (2021)

UPSHOTS IN ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA: ANALYSIS OF T-CELL BRAZIL PROJECT
por: Carlos CHIATTONE, et al.
Publicado: (2021)

Monomorphic epitheliotropic intestinal T-cell lymphoma of the duodenum: an aggressive disease
por: Ganesh Kasinathan
Publicado: (2021)